Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:41:09.715Z.
Calculation as of: 2026-10-06T20:41:09.715Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c853c120bd8ccf37c7f587defdd96232933b3c15f4f3e57031eea60a2967291
PE RATIO
N/A
Market Cap
$12.78M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dare Bioscience, Inc. (DARE) | $12.48M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | N/A | N/A | N/A | N/A |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.17M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.06M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.93M | N/A | 9.63 | 9.63 | 9.63 |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $11.77M | N/A | 245.86 | 105.92 | 78.24 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.83
Forward EPS (Est.)
$-0.78
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
